The Technical Analyst
Voyager Therapeutics Inc [VYGR]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Voyager Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-2.25% $8.24
America/New_York / 15 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 447.44 mill |
| EPS: | 2.97 |
| P/E: | 2.77 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 54.30 mill |
| Avg Daily Volume: | 0.641 mill |
| RATING 2024-04-15 |
|---|
| A+ |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Neutral | |
| P/E: | Buy | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 2.77 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.47x |
| Company: PE 2.77 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 7.65 - 8.83 ( +/- 7.11%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-01 | Ferguson Toby | Buy | 105 000 | Common Stock |
| 2024-04-02 | Swartz Robin | Sell | 1 357 | Common Stock |
| 2024-04-02 | Sandrock Alfred | Sell | 12 115 | Common Stock |
| 2024-03-25 | Ferguson Toby | Buy | 210 000 | Stock Option (Right to Buy) |
| 2024-03-25 | Ferguson Toby | Buy | 0 |
| INSIDER POWER |
|---|
| 44.02 |
| Last 94 transactions |
| Buy: 7 546 876 | Sell: 3 757 926 |
Forecast:
16:00 - $8.24
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $8.24
Forecast 2: 16:00 - $8.24
Forecast 3: 16:00 - $8.24
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $8.24 (-2.25% ) |
| Volume | 0.444 mill |
| Avg. Vol. | 0.641 mill |
| % of Avg. Vol | 69.32 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For VYGR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $7.44 | N/A | Active |
|---|
VYGR
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Last 10 Buy Signals
| Date | Signal | @ |
|---|---|---|
| NYKD.OL | Apr 16 - 08:28 | 12.90 |
| ^STOXX | Apr 16 - 08:26 | 499.53 |
| OHMUSD | Apr 16 - 08:39 | 12.17 |
| MOWI.OL | Apr 16 - 08:25 | NOK187.05 |
| PEXIP.OL | Apr 16 - 08:24 | NOK27.90 |
| NEL.OL | Apr 16 - 08:24 | NOK4.98 |
| ^STOXX50E | Apr 16 - 08:23 | PTS4 932.02 |
| ^GDAXI | Apr 16 - 08:23 | PTS17 829 |
| FTSEMIB.MI | Apr 16 - 08:23 | 33 511 |
| AKER.OL | Apr 16 - 08:22 | NOK636.00 |
Latest Press Releases
2024-04-16 07:00:00 - Press Release
Voyager Therapeutics Announces Selection Of Development Candidate For Gba1 Program In Collaboration With Neurocrine Biosciences, Triggering Milestone Payment
Lexington, mass., april 16, 2024 (globe newswire) -- voyager therapeutics, inc. (nasdaq: vygr), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator neurocrine biosciences has selected a lead development candidate in the gba1 gene therapy program for the potential treatment of parkinson's disease and other gba1-mediated diseases. the candidate combines a gba1 gene replacement payload with an intravenously administered, blood-brain barrier penetrant, novel capsid derived from voyager's tracer™ capsid discovery platform. the companies expect to file an investigational new drug (ind) application with the fda for the program in 2025.
2024-03-26 16:01:00 - Press Release
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Lexington, mass., march 26, 2024 (globe newswire) -- voyager therapeutics, inc. (nasdaq: vygr), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment agreement with toby ferguson, m.d., ph.d. that, among other things, provides for the grant to dr. ferguson of a non-qualified stock option and restricted stock units as an inducement material to dr. ferguson's entering into employment with voyager. the inducement awards were approved by the compensation committee of voyager's board of directors in accordance with nasdaq stock market listing rule 5635(c)(4). the option award became effective on march 25, 2024, and the restricted stock unit award is scheduled to become effective on april 1, 2024.
2024-03-13 07:00:00 - Press Release
Voyager Therapeutics Announces Appointment Of Toby Ferguson As Chief Medical Officer
Lexington, mass., march 13, 2024 (globe newswire) -- voyager therapeutics, inc. (nasdaq: vygr), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of toby ferguson, m.d., ph.d., as chief medical officer (cmo), effective march 25, 2024. ferguson is a skilled and experienced healthcare executive with a proven record in advancing portfolios of novel therapies across diverse indications in central nervous system (cns), neuromuscular, and rare diseases. he most recently served as vice president, head of neuromuscular development unit at biogen, inc.
2024-02-28 16:01:00 - Press Release
Voyager Therapeutics Reports Fourth Quarter And Full Year 2023 Financial And Operating Results
- company had approximately $431 million in pro-forma cash as of december 31, 2023, adjusted for $100 million consideration from novartis agreements and $100 million public offering -
2024-02-26 07:00:00 - Press Release
Voyager Therapeutics Announces Selection Of Gene Therapy Development Candidate For Friedreich's Ataxia In Collaboration With Neurocrine Biosciences, Triggering Milestone Payment
Lexington, mass., feb. 26, 2024 (globe newswire) -- voyager therapeutics, inc. (nasdaq: vygr), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator neurocrine biosciences has selected a lead development candidate in the friedreich's ataxia (fa) program. the candidate combines a frataxin (fxn) gene replacement payload with an intravenously administered, blood-brain barrier penetrant, novel capsid derived from voyager's tracer™ capsid discovery platform. the companies expect the program to advance into first-in-human clinical trials in 2025.
Latest News
2024-03-27 13:57:50 - InvestorPlace
The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio
With the market trading near all-time highs, undervalued healthcare stocks offer a compelling opportunity. Fundamentally, the sector could benefit from a rotation in the innovation ecosystem.
2024-03-21 15:56:56 - InvestorPlace
Cheap Thrills: 7 Promising Value Stocks You Can Buy for Under $20
If soaring consumer prices got you down, you may want to consider these value stocks under $20. Sure, the market may be booming during this unique post-pandemic cycle.
2024-03-13 13:11:39 - Seeking Alpha
Voyager Therapeutics: On Track To Deliver High Returns On Investment
The company's strength lies in its TRACER capsids technology that can deliver therapeutic molecules to the brain, leading to multimillion-dollar deals with pharmaceutical giants, such as Novartis. Despite the risks and uncertainties, long-term investors may be rewarded once the company's products reach clinical trial validation. Voyager's investors should expect share price volatility. Nonetheless, based on my financial valuation and the potential upsides, I consider this company as a “buy”.
2024-03-08 15:25:00 - Seeking Alpha
Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier
2024-02-28 23:02:10 - Seeking Alpha
Voyager Therapeutics, Inc. (VYGR) Q4 2023 Earnings Call Transcript
2024-02-26 15:20:23 - InvestorPlace
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet.
2024-02-21 07:00:00 - GlobeNewsWire
Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast
LEXINGTON, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2023 financial and operating results after market close on Wednesday, February 28, 2024. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET to review its financial and operating results.
2024-02-07 07:00:00 - GlobeNewsWire
Voyager Therapeutics to Present at the Oppenheimer Annual Life Sciences Conference
LEXINGTON, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Chief Financial Officer Peter Pfreundschuh will present at the Oppenheimer Life Sciences Conference on February 14, 2024, at 11:20 a.m. ET.
2024-01-11 22:09:02 - InvestorPlace
Financial Frontrunners: 3 Stocks Where the Big Money Is Moving in 2024
The financial markets in 2024 will be pulsating with transformative opportunities driven by companies poised to redefine industries. This is leading to several 2024 investment trends making themselves known, and several stocks gaining traction.
2024-01-08 09:25:03 - MarketBeat
Voyager Therapeutics stock pops 30% on deal with Novartis
Voyager Therapeutics Inc. NASDAQ: VYGR is a biotech in the medical sector that specializes in gene therapy for neurological diseases. Its shares took a 30% spike on news of its partnership with Novartis AG NYSE: NVS.